Anthony Rusk1, Elizabeth Cozzi2, Rick Sharpee2, David Vail3, Joanne Graham4, Barbara Kitchell, Chand Khanna1. Animal Cancer Institute LLC1, Columbia, MD, Abbott Laboratories, Inc2, N. Chicago, IL University of Wisconsin School of Veterinary Medicine3, Madison, WI Arboretum View Animal Hospital4, Downers Grove, IL, University of Illinois School of Veterinary Medicine5.
Thrombospondin-1 (TSP-1), a natural angiogenesis inhibitor, has been found to act broadly against a wide variety of proangiogenic growth factors. Its large molecular size and multifunctional nature has precluded its use as a therapeutic agent. Modified peptide segments of the antiangiogenic domain …

Chand Khanna, Elizabeth Cozzi, Richard Sharpee, David Vail, Joanne Graham, Barbara Kitchell, Tony Rusk
Background:
Thrombospondin-1 (TSP-1) is a natural antiangiogenic protein that enhances apoptosis of activated endothelial cells (EC). A modified nonapeptide from thrombospondin-1, ABT-526, has been found to be active in mouse cancer models and in dogs with naturally occurring cancers.
Methods:
To assess the safety and efficacy of ABT-526 when given in combination with Lomustine chemotherapy, 94 pet dogs with naturally occurring non-Hodgkin’s lymphoma (NHL), in their first relapse, were entered to a prospective randomized placebo controlled double-blinded clinical trial. Dogs …

EVALUATION OF THE ORAL ANTIMITOTIC, ABT-751, ALONE AND IN COMBINATION AN ANTIANGIOGENIC PEPTIDE OF THROMBOSPONDIN-1, ABT-510, IN DOGS WITH LYMPHOMA
M Silver, T Rusk, C Khanna, Animal Clinical Investigation, Bethesda, Maryland 20817
E-mail Michele Silver
Introduction: Previous studies defined the MTD of ABT-751 in dogs with lymphoma to be 350 mg/m2. Dose limiting toxicities (DLT) were gastrointestinal, including vomiting and diarrhea. Early evidence of clinical activity was observed at this dose. ABT-510, an oral antiangiogenic agent has resulted in efficacy in open-label treatment of dogs with a variety of cancers, including lymphoma.
Methods: …